TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Titel:
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Auteur:
Mayer, E.L. Abramson, V. Jankowitz, R. Falkson, C. Marcom, P.K. Traina, T. Carey, L. Rimawi, M. Specht, J. Miller, K. Stearns, V. Tung, N. Perou, C. Richardson, A.L. Componeschi, K. Trippa, L. Tan-Wasielewski, Z. Timms, K. Krop, I. Wolff, A.C. Winer, E.P.